Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

QUANTUM GENOMICS : Update of Shareholding Situation Following April 27, 2022 Capital Raise


Update of Shareholding Situation Following April 27, 2022 Capital Raise

Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specialising in the development of a new class of medicinal products that act directly on the brain in order to address difficult-to-treat/resistant hypertension and heart failure, updates the shareholding situation and the number of shares after its April 27, 2022 capital raise

Post-transaction capitalization table including Julphar's investment

Shareholding before operation Number of shares Percentage   Shareholding after operation   Number of shares Percentage
Téthys 993,161 3.6%   Téthys   993,161 2.9%
Otium Capital 888,888 3.3%   Otium Capital   4,987,248 14.4%
Investisseurs institutionnels 5,405,810 19.7%   Investisseurs institutionnels   7,716,229 22.3%
Management 1,740,983 6.3%   Management   1,740,983 5.0%
Public 18,414,446 67.1%   Public   18,414,446 53.2%
  Julphar   767,914 2.2%
Total 27,443,288 100.0%   Total   34,619,981 100.0%

As an example, a shareholder with 1.00% of the Company's capital before the Deal and Julphar's subscribed capital increase would henceforth hold a stake of 0.79%.

About Quantum Genomics

Quantum Genomics is a biopharmaceutical company specializing in the development of a new class cardiovascular drugs based on the Brain Aminopeptidase A Inhibition (BAPAI) mechanism. It is the only company in the world to pursue this innovative approach directly targeting the brain, founded upon more than twenty years of research work by Paris-Descartes University and the INSERM/CNRS laboratory led by Dr. Catherine Llorens-Cortès at the Collège de France. Quantum Genomics thus aims to develop innovative treatments for complicated or even treatment-resistant hypertension (in approximately 30% of patients it is poorly controlled or treatment failure occurs), and heart failure (one in two patients diagnosed dies within five years).

Based in Paris and New York, the company is listed on the Euronext Growth market in Paris (FR0011648971 - ALQGC) and is registered on the US OTCQX market (symbol: QNNTF).

Find out more at www.quantum-genomics.com, or on our Twitter and Linkedin accounts

Contacts

Quantum Genomics  
[email protected]  
Edifice Communication (EUROPE)  
Financial and media communication
[email protected]
 
LifeSci (USA)  
Mike Tattory
Media communication
+1 (646) 751-4362 - [email protected]
 


This publication embed "🔒 Actusnews SECURITY MASTER".
- SECURITY MASTER Key: nG1uYpRuaGqWnG9rlZ6YmmlrmJxjxGibmGHKlWWZZZqVmXKUymeXa5ycZnBllm1o
- Check this key: https://www.security-master-key.com.



Regulated information:
Total number of voting rights and capital:
- Information on the total number of voting rights and shares making up the share capital


Full and original press release in PDF: https://www.actusnews.com/news/74182-information-reglementee-27042022-en-anglais.pdf

Receive by email the next press releases of the company by registering on www.actusnews.com, it's free

Source Actusnews

Quantum Genomics S.A. Stock

€0.093
-1.280%
A loss of -1.280% shows a downward development for Quantum Genomics S.A..

Like: 0
Share

Comments